Identification of N-Acetyltransferase 2 (NAT2) Transcription Start Sites and Quantitation of NAT2-Specific mRNA in Human Tissues
Authors:
- Xiaoyan ZhangXZXiaoyan Zhang
- Mark A. DollMDMark A. Doll
- J. Christopher StatesJSJ. Christopher States
- David F. BarkerDBDavid F. Barker
- David W. HeinDHDavid W. Hein
- 1 May 2007
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 35 (5) , 721-727
Abstract
Human N-acetyltransferase 2 (NAT2) genetic polymorphism is associated with drug toxicity and/or carcinogenesis in various tissues. Knowledge of NAT2 gene structure and expression is critical for understanding these associations. Previous findings suggest that human NAT2 expression is highest in liver and gut but expressed at functional levels in other tissues. A sensitive and specific TaqMan reverse transcriptase-polymerase chain reaction (RT-PCR) assay with intron-spanning primers was developed and used, together with a second TaqMan RT-PCR assay based on amplification of a NAT2 open reading frame (ORF) exon segment, to measure NAT2 mRNA in 29 different human tissues. Cap-dependent amplification of mRNA 5′ termini and review of public database information were done to more precisely define the NAT2 promoter(s) and to validate the quantitative RT-PCR assay design. The great majority (40/41) of NAT2 liver cDNAs had 5′ termini between 8682 and 8752 nucleotides upstream of the NAT2 ORF exon, and 34 of 40 5′ termini were at the –8711 and –8716 adenines. All 59 NAT2 cDNAs with 5′ termini in this vicinity, including 40 of the liver isolates and 19 cDNAs in public databases from liver and other sources, showed direct splicing to the ORF exon, with no other noncoding exon detected. NAT2 mRNA was highest in liver, small intestine, and colon and was readily detected in most other tissues, albeit at much lower levels. NAT2 expression in diverse human tissues provides further mechanistic support underlying associations between NAT2 genetic polymorphism, drug toxicity, and/or chemical carcinogenesis.Keywords
This publication has 36 references indexed in Scilit:
- N-Acetyltransferase (Nat) 1 and 2 Expression in Nat2 Knockout MiceThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Functional properties of an alternative, tissue-specific promoter for human arylamine N-acetyltransferase 1Pharmacogenetics and Genomics, 2006
- Tissue distribution of N ‐acetyltransferase 1 and 2 catalyzing the N ‐acetylation of 4‐aminobiphenyl and O ‐acetylation of N ‐hydroxy‐4‐aminobiphenyl in the congenic rapid and slow acetylator Syrian hamsterMolecular Carcinogenesis, 2006
- NAT2 slow acetylation and bladder cancer in workers exposed to benzidineInternational Journal of Cancer, 2005
- Neonatal Ontogeny of Murine Arylamine N-Acetyltransferases: Implications for Arylamine GenotoxicityToxicological Sciences, 2003
- The Human Genome Browser at UCSCGenome Research, 2002
- BLAT—The BLAST-Like Alignment ToolGenome Research, 2002
- Pharmacogenetics of the arylamine N-acetyltransferasesThe Pharmacogenomics Journal, 2002
- Acetylation polymorphism expression in patients before and after liver transplantationPharmacogenetics, 1998
- Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.Journal of Clinical Investigation, 1990